Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma

scientific article

Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.EURURO.2013.12.017
P932PMC publication ID4071134
P698PubMed publication ID24388441

P50authorRichard W. JosephQ38524195
P2093author name stringBradley C Leibovich
Jeanette E Eckel-Passow
John C Cheville
Mansi Parasramka
Alexander S Parker
Kevin J Wu
Daniel Serie
Tracy Hilton
P2860cites workRising incidence of renal cell cancer in the United StatesQ46854143
Serendipitous renal cell carcinoma in the post-CT era: continued evidence in improved outcomesQ47988904
Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis.Q51154107
Topoisomerase IIalpha expression in breast cancer: correlation with outcome variablesQ73821356
Topoisomerase II as a target for anticancer drugs: when enzymes stop being niceQ33851826
Functional and regulatory characteristics of eukaryotic type II DNA topoisomeraseQ34188390
Innovations and challenges in renal cancer: consensus statement from the first international conferenceQ35901560
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.Q36119612
The association of topoisomerase 2α expression with prognosis in surgically resected non-small cell lung cancer (NSCLC) patientsQ36186309
Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancerQ36621348
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothingQ37108461
DNA topoisomerase II and its growing repertoire of biological functions.Q37313703
External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathologyQ37343211
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinomaQ37461830
Epidemiology of renal cell cancerQ37901838
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errorsQ39605793
External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinomaQ40058539
An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN scoreQ44231764
Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinomaQ44605433
P433issue5
P407language of work or nameEnglishQ1860
P304page(s)929-935
P577publication date2013-12-25
P1433published inEuropean UrologyQ15763991
P1476titleHigher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma
P478volume66

Reverse relations

cites work (P2860)
Q47812859Alcohol consumption, variability in alcohol dehydrogenase genes and risk of renal cell carcinoma
Q38861806Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.
Q36317488BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
Q37573538Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.
Q37520405Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects
Q33751222DNA topoisomerase IIα and Ki67 are prognostic factors in patients with hepatocellular carcinoma
Q38938193Evaluation of NIN/RPN12 binding protein inhibits proliferation and growth in human renal cancer cells
Q35405080Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma
Q41221347High Expression of Colony-Stimulating Factor 1 Receptor Associates with Unfavorable Cancer-Specific Survival of Patients with Clear Cell Renal Cell Carcinoma
Q64899492High expression of herpes virus entry mediator is associated with poor prognosis in clear cell renal cell carcinoma.
Q41709688High mucin 5AC expression predicts adverse postoperative recurrence and survival of patients with clear-cell renal cell carcinoma
Q92068655Identification of Four Pathological Stage-Relevant Genes in Association with Progression and Prognosis in Clear Cell Renal Cell Carcinoma by Integrated Bioinformatics Analysis
Q90032980LncRNA SNHG3 promotes clear cell renal cell carcinoma proliferation and migration by upregulating TOP2A
Q34459467NPRL-Z-1, as a new topoisomerase II poison, induces cell apoptosis and ROS generation in human renal carcinoma cells
Q64898393Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
Q37433431Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma
Q92881600Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms
Q37582692ZNF148 modulates TOP2A expression and cell proliferation via ceRNA regulatory mechanism in colorectal cancer.